Entod Pharmaceuticals Secures DCGI Nod for Innovative Eye Drops for Presbyopia

Entod Pharmaceuticals has received approval from the Drug Controller General of India (DCGI) to market PresVu eye drops, the first in India developed to reduce reading glasses dependency for presbyopia. The company plans to introduce the product domestically by early October and aims to serve domestic and emerging markets.

Entod Pharmaceuticals on Tuesday announced it has secured approval from the Drug Controller General of India (DCGI) to market its PresVu eye drops for treating presbyopia.

The Mumbai-based drugmaker received final approval for PresVu and plans to introduce it in the domestic market by the first week of October. This approval follows a recommendation by the Subject Expert Committee (SEC) of the Central Drugs Standard Control Organisation (CDSCO).

PresVu is set to become India's first eye drop specifically developed to reduce dependency on reading glasses for individuals affected by presbyopia, a common age-related vision condition typically impacting those over 40. Entod Pharmaceuticals CEO Nikkhil K Masurkar highlighted the importance of this approval, stating, "This DCGI approval is a major step forward in our mission to transform eye care in India."

(With inputs from agencies.)